Chronic kidney illness (CKD) is amongst the most prevalent and dire problems of diabetes mellitus in adults throughout the world. Diabetes considerably contributes to the burden of kidney illness, such that one third to at least one half of CKD in the United States and many different international locations is attributable to diabetic kidney illness (DKD). As DKD progresses to end-stage renal illness (ESRD), sufferers are at heightened danger for atypical glycemic problems, together with the improvement of burnt-out diabetes, manifested by hypoglycemic bouts and poor outcomes.
Furthermore, even in the absence of diabetes, hypoglycemia is a frequent incidence in CKD sufferers which will contribute to their excessive burden of heart problems and demise. Extrapolation of knowledge from scientific trials in high-cardiovascular-risk populations and observational research in sufferers with non-dialysis-dependent (NDD) CKD and ESRD recommend that reasonable glycemic targets outlined by glycated hemoglobin ranges of 6% to eight% and glucose ranges of 100 to 150 mg/dL are related to higher survival in DKD sufferers.
However, given the imprecision of glycated hemoglobin ranges in kidney illness, additional analysis is required to find out the optimum glycemic metric and goal in diabetic NDD-CKD and ESRD sufferers. Given their exceedingly excessive cardiovascular morbidity and mortality, there’s a compelling want for additional investigation of the way to optimally handle dysglycemia in the NDD-CKD and ESRD populations.
Dendritic Integration Dysfunction in Neurodevelopmental Disorders
Neurodevelopmental issues (NDDs) that have an effect on cognition, social interplay, and studying, together with autism spectrum dysfunction (ASD) and mental incapacity (ID), have a powerful genetic element. Our present understanding of danger genes highlights two most important teams of dysfunction: these in genes that act as chromatin modifiers and these in genes that encode for proteins localized at or close to synapses. Understanding how dysfunction in these genes contributes to phenotypes noticed in ASD and ID stays a serious query in neuroscience.
In this overview, we spotlight rising proof suggesting that dysfunction in dendrites – areas of neurons that obtain synaptic enter – could also be key to understanding options of neuronal processing affected in these issues. Dendritic integration performs a basic function in sensory processing, cognition, and acutely aware notion, processes hypothesized to be impaired in NDDs. Many high-confidence ASD genes perform inside dendrites the place they management synaptic integration and dendritic excitability.
Further, growing proof demonstrates that a number of ASD/ID genes, together with chromatin modifiers and transcription components, regulate the expression or scaffolding of dendritic ion channels, receptors, and synaptic proteins. Therefore, we talk about how dysfunction of subsets of NDD-associated genes in dendrites results in defects in dendritic integration and excitability and could also be one core phenotype in ASD and ID.
In vitro dissolution concerns related to nano drug supply techniques
Nano drug supply techniques (NDDS) supply promising answer for the translation of future nanomedicines. As bioavailability and therapeutic outcomes may be improved by altering the drug launch from these NDDS, it turns into important to completely perceive their drug launch kinetics. Moreover, U.S. Food and Drug Administration requires essential analysis of potential security, efficacy, and public well being impacts of nanomaterials. Spiraling up market share of NDDS has additionally stimulated the pharmaceutical trade to develop their cost-effective generic variations after the expiry of patent and related exclusivity.
However, in contrast to the standard dosage types, the in vivo disposition of NDDS is very intricate and totally different from their in vitro habits. Significant challenges exist in the institution of in vitro-in vivo correlation (IVIVC) attributable to incomplete understanding of nanoparticles’ in vivo biofate and its influence on in vitro experimental protocols. A rational design of dissolution might function high quality and amount management instrument and assist develop a significant IVIVC for favorable financial implications. Clinically related drug product specs (essential high quality attributes) may be recognized by establishing a hyperlink between in vitro efficiency and in vivo publicity.
In vitro dissolution can also play a pivotal function to know the dissolution-mediated clearance and security of NDDS. Prevalent in vitro dissolution strategies for NDDS and their limitations are mentioned in this overview, amongst which USP four is gaining extra curiosity lately. Researchers are working diligently to develop biorelevant in vitro launch assays to make sure optimum therapeutic efficiency of generic variations of those NDDS. This article focuses on these research and presents vital concerns for the future improvement of clinically related in vitro launch strategies.
A overview of the proof on the danger of congenital malformations and neurodevelopmental issues in affiliation with antiseizure medicines throughout being pregnant
IntroductionThe majority of ladies with epilepsy require remedy with antiseizure medicines (ASM) all through being pregnant. However, in utero publicity to a number of ASM has been related to an elevated danger of congenital malformations and/or neurodevelopmental issues (CM/NDD) in the baby, however observational proof is methodologically heterogeneous.Areas coatedWe critically consider present proof on the danger of CM/NDD in youngsters of ladies with epilepsy after in utero publicity to totally different ASM.
We spotlight traits of various information sources and talk about their advantages and drawbacks. This overview consists of proof revealed earlier than December 2020 (non-systematic literature search).Expert opinionGiven the lack of randomized managed trials, proof on in utero security of ASM originates from methodologically heterogeneous post-marketing observational research primarily based on registries, potential cohorts, and giant digital well being databases.
Dbndd1 ORF Vector (Mouse) (pORF) |
|||
| ORF042642 | ABM | 1.0 ug DNA | 607.2 EUR |
Dbndd1 ORF Vector (Mouse) (pORF) |
|||
| ORF042643 | ABM | 1.0 ug DNA | 607.2 EUR |
Dbndd1 ORF Vector (Mouse) (pORF) |
|||
| ORF042644 | ABM | 1.0 ug DNA | 607.2 EUR |
Dbndd1/ Rat Dbndd1 ELISA Kit |
|||
| ELI-46842r | Lifescience Market | 96 Tests | 1063.2 EUR |
DBNDD1 Protein Vector (Rat) (pPM-C-HA) |
|||
| PV263164 | ABM | 500 ng | 723.6 EUR |
DBNDD1 Protein Vector (Rat) (pPB-C-His) |
|||
| PV263162 | ABM | 500 ng | 723.6 EUR |
DBNDD1 Protein Vector (Rat) (pPB-N-His) |
|||
| PV263163 | ABM | 500 ng | 723.6 EUR |
DBNDD1 Protein Vector (Rat) (pPM-C-His) |
|||
| PV263165 | ABM | 500 ng | 723.6 EUR |
DBNDD1 Protein Vector (Mouse) (pPM-C-HA) |
|||
| PV170568 | ABM | 500 ng | 723.6 EUR |
DBNDD1 Protein Vector (Mouse) (pPM-C-HA) |
|||
| PV170572 | ABM | 500 ng | 723.6 EUR |
DBNDD1 Protein Vector (Mouse) (pPM-C-HA) |
|||
| PV170576 | ABM | 500 ng | 723.6 EUR |
DBNDD1 Protein Vector (Human) (pPM-C-HA) |
|||
| PV072235 | ABM | 500 ng | 662.4 EUR |
DBNDD1 Protein Vector (Mouse) (pPB-C-His) |
|||
| PV170566 | ABM | 500 ng | 723.6 EUR |
DBNDD1 Protein Vector (Mouse) (pPB-N-His) |
|||
| PV170567 | ABM | 500 ng | 723.6 EUR |
DBNDD1 Protein Vector (Mouse) (pPM-C-His) |
|||
| PV170569 | ABM | 500 ng | 723.6 EUR |
DBNDD1 Protein Vector (Mouse) (pPB-C-His) |
|||
| PV170570 | ABM | 500 ng | 723.6 EUR |
DBNDD1 Protein Vector (Mouse) (pPB-N-His) |
|||
| PV170571 | ABM | 500 ng | 723.6 EUR |
DBNDD1 Protein Vector (Mouse) (pPM-C-His) |
|||
| PV170573 | ABM | 500 ng | 723.6 EUR |
DBNDD1 Protein Vector (Mouse) (pPB-C-His) |
|||
| PV170574 | ABM | 500 ng | 723.6 EUR |
DBNDD1 Protein Vector (Mouse) (pPB-N-His) |
|||
| PV170575 | ABM | 500 ng | 723.6 EUR |
DBNDD1 Protein Vector (Mouse) (pPM-C-His) |
|||
| PV170577 | ABM | 500 ng | 723.6 EUR |
DBNDD1 Protein Vector (Human) (pPB-C-His) |
|||
| PV072233 | ABM | 500 ng | 662.4 EUR |
DBNDD1 Protein Vector (Human) (pPB-N-His) |
|||
| PV072234 | ABM | 500 ng | 662.4 EUR |
DBNDD1 Protein Vector (Human) (pPM-C-His) |
|||
| PV072236 | ABM | 500 ng | 662.4 EUR |
DBNDD1 siRNA |
|||
| 20-abx913603 | Abbexa |
|
|
DBNDD1 siRNA |
|||
| 20-abx913604 | Abbexa |
|
|
DBNDD1 siRNA |
|||
| 20-abx901417 | Abbexa |
|
|
DBNDD1 Protein |
|||
| 20-abx260921 | Abbexa |
|
|
Dbndd1 sgRNA CRISPR Lentivector set (Rat) |
|||
| K6273401 | ABM | 3 x 1.0 ug | 406.8 EUR |
Human DBNDD1 Antibody |
|||
| 33409-05111 | AssayPro | 150 ug | 313.2 EUR |
DBNDD1 sgRNA CRISPR Lentivector set (Human) |
|||
| K0563301 | ABM | 3 x 1.0 ug | 406.8 EUR |
Dbndd1 sgRNA CRISPR Lentivector set (Mouse) |
|||
| K3858501 | ABM | 3 x 1.0 ug | 406.8 EUR |
DBNDD1 protein (His tag) |
|||
| 80R-2386 | Fitzgerald | 100 ug | 386.4 EUR |
|
Description: Purified recombinant Human DBNDD1 protein (His tag) |
|||
Dbndd1 sgRNA CRISPR Lentivector (Rat) (Target 1) |
|||
| K6273402 | ABM | 1.0 ug DNA | 184.8 EUR |
Dbndd1 sgRNA CRISPR Lentivector (Rat) (Target 2) |
|||
| K6273403 | ABM | 1.0 ug DNA | 184.8 EUR |
Dbndd1 sgRNA CRISPR Lentivector (Rat) (Target 3) |
|||
| K6273404 | ABM | 1.0 ug DNA | 184.8 EUR |
Rat DBNDD1 shRNA Plasmid |
|||
| 20-abx990198 | Abbexa |
|
|
DBNDD1 sgRNA CRISPR Lentivector (Human) (Target 1) |
|||
| K0563302 | ABM | 1.0 ug DNA | 184.8 EUR |
DBNDD1 sgRNA CRISPR Lentivector (Human) (Target 2) |
|||
| K0563303 | ABM | 1.0 ug DNA | 184.8 EUR |
DBNDD1 sgRNA CRISPR Lentivector (Human) (Target 3) |
|||
| K0563304 | ABM | 1.0 ug DNA | 184.8 EUR |
Dbndd1 sgRNA CRISPR Lentivector (Mouse) (Target 1) |
|||
| K3858502 | ABM | 1.0 ug DNA | 184.8 EUR |
Dbndd1 sgRNA CRISPR Lentivector (Mouse) (Target 2) |
|||
| K3858503 | ABM | 1.0 ug DNA | 184.8 EUR |
Dbndd1 sgRNA CRISPR Lentivector (Mouse) (Target 3) |
|||
| K3858504 | ABM | 1.0 ug DNA | 184.8 EUR |
Mouse DBNDD1 shRNA Plasmid |
|||
| 20-abx977710 | Abbexa |
|
|
Human DBNDD1 shRNA Plasmid |
|||
| 20-abx962250 | Abbexa |
|
|
DBNDD1 Recombinant Protein (Rat) |
|||
| RP197369 | ABM | 100 ug | Ask for price |
DBNDD1 Recombinant Protein (Mouse) |
|||
| RP127922 | ABM | 100 ug | Ask for price |
DBNDD1 Recombinant Protein (Mouse) |
|||
| RP127925 | ABM | 100 ug | Ask for price |
DBNDD1 Recombinant Protein (Mouse) |
|||
| RP127928 | ABM | 100 ug | Ask for price |
DBNDD1 Recombinant Protein (Human) |
|||
| RP054174 | ABM | 100 ug | Ask for price |
Human DBNDD1 Antibody (Biotin Conjugate) |
|||
| 33409-05121 | AssayPro | 150 ug | 442.8 EUR |
Dbndd1 sgRNA CRISPR/Cas9 All-in-One Lentivector set (Rat) |
|||
| K6273405 | ABM | 3 x 1.0 ug | 451.2 EUR |
DBNDD1 sgRNA CRISPR/Cas9 All-in-One Lentivector set (Human) |
|||
| K0563305 | ABM | 3 x 1.0 ug | 451.2 EUR |
Dbndd1 sgRNA CRISPR/Cas9 All-in-One Lentivector set (Mouse) |
|||
| K3858505 | ABM | 3 x 1.0 ug | 451.2 EUR |
Dbndd1 3'UTR GFP Stable Cell Line |
|||
| TU154864 | ABM | 1.0 ml | Ask for price |
DBNDD1 3'UTR GFP Stable Cell Line |
|||
| TU055580 | ABM | 1.0 ml | 1672.8 EUR |
Dbndd1 3'UTR GFP Stable Cell Line |
|||
| TU253166 | ABM | 1.0 ml | Ask for price |
Dbndd1 sgRNA CRISPR/Cas9 All-in-One Lentivector (Rat) (Target 1) |
|||
| K6273406 | ABM | 1.0 ug DNA | 200.4 EUR |
Dbndd1 sgRNA CRISPR/Cas9 All-in-One Lentivector (Rat) (Target 2) |
|||
| K6273407 | ABM | 1.0 ug DNA | 200.4 EUR |
Dbndd1 sgRNA CRISPR/Cas9 All-in-One Lentivector (Rat) (Target 3) |
|||
| K6273408 | ABM | 1.0 ug DNA | 200.4 EUR |
DBNDD1 sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 1) |
|||
| K0563306 | ABM | 1.0 ug DNA | 200.4 EUR |
DBNDD1 sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 2) |
|||
| K0563307 | ABM | 1.0 ug DNA | 200.4 EUR |
DBNDD1 sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 3) |
|||
| K0563308 | ABM | 1.0 ug DNA | 200.4 EUR |
Dbndd1 sgRNA CRISPR/Cas9 All-in-One Lentivector (Mouse) (Target 1) |
|||
| K3858506 | ABM | 1.0 ug DNA | 200.4 EUR |
Dbndd1 sgRNA CRISPR/Cas9 All-in-One Lentivector (Mouse) (Target 2) |
|||
| K3858507 | ABM | 1.0 ug DNA | 200.4 EUR |
Dbndd1 sgRNA CRISPR/Cas9 All-in-One Lentivector (Mouse) (Target 3) |
|||
| K3858508 | ABM | 1.0 ug DNA | 200.4 EUR |
Human DBNDD1 AssayLite Antibody (RPE Conjugate) |
|||
| 33409-05151 | AssayPro | 150 ug | 513.6 EUR |
Human DBNDD1 AssayLite Antibody (APC Conjugate) |
|||
| 33409-05161 | AssayPro | 150 ug | 513.6 EUR |
DBNDD1 3'UTR Luciferase Stable Cell Line |
|||
| TU005580 | ABM | 1.0 ml | 1672.8 EUR |
Dbndd1 3'UTR Luciferase Stable Cell Line |
|||
| TU203166 | ABM | 1.0 ml | Ask for price |
Dbndd1 3'UTR Luciferase Stable Cell Line |
|||
| TU104864 | ABM | 1.0 ml | Ask for price |
Human DBNDD1 AssayLite Antibody (FITC Conjugate) |
|||
| 33409-05141 | AssayPro | 150 ug | 513.6 EUR |
Human DBNDD1 AssayLite Antibody (PerCP Conjugate) |
|||
| 33409-05171 | AssayPro | 150 ug | 565.2 EUR |
Recombinant Human DBNDD1 Protein, His, E.coli-1mg |
|||
| QP11597-1mg | EnQuireBio | 1mg | 3308.4 EUR |
Recombinant Human DBNDD1 Protein, His, E.coli-5ug |
|||
| QP11597-5ug | EnQuireBio | 5ug | 186 EUR |
Recombinant Human DBNDD1 Protein, His, E.coli-20ug |
|||
| QP11597-20ug | EnQuireBio | 20ug | 241.2 EUR |
Human Dysbindin domain- containing protein 1, DBNDD1 ELISA KIT |
|||
| ELI-46841h | Lifescience Market | 96 Tests | 988.8 EUR |
Mouse Dysbindin domain- containing protein 1, Dbndd1 ELISA KIT |
|||
| ELI-31886m | Lifescience Market | 96 Tests | 1038 EUR |
Bovine Dysbindin domain- containing protein 1, DBNDD1 ELISA KIT |
|||
| ELI-46840b | Lifescience Market | 96 Tests | 1113.6 EUR |
Dbndd2 ORF Vector (Rat) (pORF) |
|||
| ORF065792 | ABM | 1.0 ug DNA | 607.2 EUR |
DBNDD2 ORF Vector (Human) (pORF) |
|||
| ORF002929 | ABM | 1.0 ug DNA | 114 EUR |
Dbndd2 ORF Vector (Mouse) (pORF) |
|||
| ORF042645 | ABM | 1.0 ug DNA | 607.2 EUR |
Dbndd2 ORF Vector (Mouse) (pORF) |
|||
| ORF042646 | ABM | 1.0 ug DNA | 607.2 EUR |
Dbndd2 ORF Vector (Mouse) (pORF) |
|||
| ORF042647 | ABM | 1.0 ug DNA | 607.2 EUR |
Dbndd2 ORF Vector (Mouse) (pORF) |
|||
| ORF042648 | ABM | 1.0 ug DNA | 607.2 EUR |
DBNDD2 Protein Vector (Rat) (pPM-C-HA) |
|||
| PV263168 | ABM | 500 ng | 723.6 EUR |
DBNDD2 Protein Vector (Rat) (pPB-C-His) |
|||
| PV263166 | ABM | 500 ng | 723.6 EUR |
DBNDD2 Protein Vector (Rat) (pPB-N-His) |
|||
| PV263167 | ABM | 500 ng | 723.6 EUR |
DBNDD2 Protein Vector (Rat) (pPM-C-His) |
|||
| PV263169 | ABM | 500 ng | 723.6 EUR |
DBNDD2 Protein Vector (Human) (pPM-C-HA) |
|||
| PV011715 | ABM | 500 ng | 394.8 EUR |
DBNDD2 Protein Vector (Mouse) (pPM-C-HA) |
|||
| PV170580 | ABM | 500 ng | 723.6 EUR |
DBNDD2 Protein Vector (Mouse) (pPM-C-HA) |
|||
| PV170584 | ABM | 500 ng | 723.6 EUR |
DBNDD2 Protein Vector (Mouse) (pPM-C-HA) |
|||
| PV170588 | ABM | 500 ng | 723.6 EUR |
DBNDD2 Protein Vector (Mouse) (pPM-C-HA) |
|||
| PV170592 | ABM | 500 ng | 723.6 EUR |
DBNDD2 Protein Vector (Human) (pPB-C-His) |
|||
| PV011713 | ABM | 500 ng | 394.8 EUR |
DBNDD2 Protein Vector (Human) (pPB-N-His) |
|||
| PV011714 | ABM | 500 ng | 394.8 EUR |
DBNDD2 Protein Vector (Human) (pPM-C-His) |
|||
| PV011716 | ABM | 500 ng | 394.8 EUR |
DBNDD2 Protein Vector (Mouse) (pPB-C-His) |
|||
| PV170578 | ABM | 500 ng | 723.6 EUR |
DBNDD2 Protein Vector (Mouse) (pPB-N-His) |
|||
| PV170579 | ABM | 500 ng | 723.6 EUR |
DBNDD2 Protein Vector (Mouse) (pPM-C-His) |
|||
| PV170581 | ABM | 500 ng | 723.6 EUR |
DBNDD2 Protein Vector (Mouse) (pPB-C-His) |
|||
| PV170582 | ABM | 500 ng | 723.6 EUR |
DBNDD2 Protein Vector (Mouse) (pPB-N-His) |
|||
| PV170583 | ABM | 500 ng | 723.6 EUR |
DBNDD2 Protein Vector (Mouse) (pPM-C-His) |
|||
| PV170585 | ABM | 500 ng | 723.6 EUR |
DBNDD2 Protein Vector (Mouse) (pPB-C-His) |
|||
| PV170586 | ABM | 500 ng | 723.6 EUR |
DBNDD2 Protein Vector (Mouse) (pPB-N-His) |
|||
| PV170587 | ABM | 500 ng | 723.6 EUR |
DBNDD2 Protein Vector (Mouse) (pPM-C-His) |
|||
| PV170589 | ABM | 500 ng | 723.6 EUR |
DBNDD2 Protein Vector (Mouse) (pPB-C-His) |
|||
| PV170590 | ABM | 500 ng | 723.6 EUR |
DBNDD2 Protein Vector (Mouse) (pPB-N-His) |
|||
| PV170591 | ABM | 500 ng | 723.6 EUR |
DBNDD2 Protein Vector (Mouse) (pPM-C-His) |
|||
| PV170593 | ABM | 500 ng | 723.6 EUR |
DBNDD1 Dysbindin (Dystrobrevin Binding Protein 1) Domain Containing 1 Human Recombinant Protein |
|||
| PROTQ9H9R9 | BosterBio | Regular: 20ug | 380.4 EUR |
|
Description: DBNDD1 Human Recombinant produced in E.Coli is a single, non-glycosylated polypeptide chain containing 182 amino acids (1-158 a.a) and having a molecular mass of 19.6kDa (Molecular weight on SDS-PAGE will appear higher).;DBNDD1 is fused to a 24 amino acid His-tag at N-terminus & purified by proprietary chromatographic techniques. |
|||
Dbndd2 sgRNA CRISPR Lentivector set (Rat) |
|||
| K6333201 | ABM | 3 x 1.0 ug | 406.8 EUR |
DBNDD2 sgRNA CRISPR Lentivector set (Human) |
|||
| K0563401 | ABM | 3 x 1.0 ug | 406.8 EUR |
Dbndd2 sgRNA CRISPR Lentivector set (Mouse) |
|||
| K3201701 | ABM | 3 x 1.0 ug | 406.8 EUR |
Dbndd2 sgRNA CRISPR Lentivector (Rat) (Target 1) |
|||
| K6333202 | ABM | 1.0 ug DNA | 184.8 EUR |
Dbndd2 sgRNA CRISPR Lentivector (Rat) (Target 2) |
|||
| K6333203 | ABM | 1.0 ug DNA | 184.8 EUR |
Dbndd2 sgRNA CRISPR Lentivector (Rat) (Target 3) |
|||
| K6333204 | ABM | 1.0 ug DNA | 184.8 EUR |
DBNDD2 sgRNA CRISPR Lentivector (Human) (Target 1) |
|||
| K0563402 | ABM | 1.0 ug DNA | 184.8 EUR |
DBNDD2 sgRNA CRISPR Lentivector (Human) (Target 2) |
|||
| K0563403 | ABM | 1.0 ug DNA | 184.8 EUR |
DBNDD2 sgRNA CRISPR Lentivector (Human) (Target 3) |
|||
| K0563404 | ABM | 1.0 ug DNA | 184.8 EUR |
Dbndd2 sgRNA CRISPR Lentivector (Mouse) (Target 1) |
|||
| K3201702 | ABM | 1.0 ug DNA | 184.8 EUR |
Dbndd2 sgRNA CRISPR Lentivector (Mouse) (Target 2) |
|||
| K3201703 | ABM | 1.0 ug DNA | 184.8 EUR |
Dbndd2 sgRNA CRISPR Lentivector (Mouse) (Target 3) |
|||
| K3201704 | ABM | 1.0 ug DNA | 184.8 EUR |
Dbndd2 sgRNA CRISPR/Cas9 All-in-One Lentivector set (Rat) |
|||
| K6333205 | ABM | 3 x 1.0 ug | 451.2 EUR |
DBNDD2 sgRNA CRISPR/Cas9 All-in-One Lentivector set (Human) |
|||
| K0563405 | ABM | 3 x 1.0 ug | 451.2 EUR |
Dbndd2 sgRNA CRISPR/Cas9 All-in-One Lentivector set (Mouse) |
|||
| K3201705 | ABM | 3 x 1.0 ug | 451.2 EUR |
Dbndd2 sgRNA CRISPR/Cas9 All-in-One Lentivector (Rat) (Target 1) |
|||
| K6333206 | ABM | 1.0 ug DNA | 200.4 EUR |
Dbndd2 sgRNA CRISPR/Cas9 All-in-One Lentivector (Rat) (Target 2) |
|||
| K6333207 | ABM | 1.0 ug DNA | 200.4 EUR |
Dbndd2 sgRNA CRISPR/Cas9 All-in-One Lentivector (Rat) (Target 3) |
|||
| K6333208 | ABM | 1.0 ug DNA | 200.4 EUR |
DBNDD2 sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 1) |
|||
| K0563406 | ABM | 1.0 ug DNA | 200.4 EUR |
DBNDD2 sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 2) |
|||
| K0563407 | ABM | 1.0 ug DNA | 200.4 EUR |
DBNDD2 sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 3) |
|||
| K0563408 | ABM | 1.0 ug DNA | 200.4 EUR |
Dbndd2 sgRNA CRISPR/Cas9 All-in-One Lentivector (Mouse) (Target 1) |
|||
| K3201706 | ABM | 1.0 ug DNA | 200.4 EUR |
Dbndd2 sgRNA CRISPR/Cas9 All-in-One Lentivector (Mouse) (Target 2) |
|||
| K3201707 | ABM | 1.0 ug DNA | 200.4 EUR |
Dbndd2 sgRNA CRISPR/Cas9 All-in-One Lentivector (Mouse) (Target 3) |
|||
| K3201708 | ABM | 1.0 ug DNA | 200.4 EUR |
DBNDD2 siRNA |
|||
| 20-abx913605 | Abbexa |
|
|
DBNDD2 siRNA |
|||
| 20-abx913606 | Abbexa |
|
|
DBN1 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV) |
|||
| LV660313 | ABM | 1.0 ug DNA | 1626 EUR |
DBN1 Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC) |
|||
| LV660317 | ABM | 1.0 ug DNA | 1626 EUR |
DBNDD2 Protein |
|||
| 20-abx262528 | Abbexa |
|
|
DBN1 Lentiviral Vector (Rat) (EF1a) (pLenti-GIII-EF1a) |
|||
| LV660318 | ABM | 1.0 ug DNA | 1626 EUR |
DBNDD2 Antibody |
|||
| 1-CSB-PA863102HA01HU | Cusabio |
|
|
|
Description: A polyclonal antibody against DBNDD2. Recognizes DBNDD2 from Human. This antibody is Unconjugated. Tested in the following application: ELISA, IHC; Recommended dilution: IHC:1:20-1:200 |
|||
DBNDD2 Antibody |
|||
| 20-abx301648 | Abbexa |
|
|
DBNDD2 protein (His tag) |
|||
| 80R-2396 | Fitzgerald | 50 ug | 508.8 EUR |
|
Description: Purified recombinant Human DBNDD2 protein (His tag) |
|||
DBNDD2 Antibody (HRP) |
|||
| 20-abx310704 | Abbexa |
|
|
DBNDD2 Antibody (FITC) |
|||
| 20-abx310705 | Abbexa |
|
|
DBNDD2 cloning plasmid |
|||
| CSB-CL863102HU-10ug | Cusabio | 10ug | 279.6 EUR |
|
Description: A cloning plasmid for the DBNDD2 gene. |
|||
DBNDD2 Antibody (Biotin) |
|||
| 20-abx310706 | Abbexa |
|
|
Dbndd2 3'UTR GFP Stable Cell Line |
|||
| TU154865 | ABM | 1.0 ml | Ask for price |
DBNDD2 3'UTR GFP Stable Cell Line |
|||
| TU055581 | ABM | 1.0 ml | 1825.2 EUR |
Dbndd2 3'UTR GFP Stable Cell Line |
|||
| TU253167 | ABM | 1.0 ml | Ask for price |
Mouse DBNDD2 shRNA Plasmid |
|||
| 20-abx974293 | Abbexa |
|
|
Human DBNDD2 shRNA Plasmid |
|||
| 20-abx960978 | Abbexa |
|
|
DBNL Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV) |
|||
| LV626185 | ABM | 1.0 ug DNA | 818.4 EUR |
DBNL Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC) |
|||
| LV626189 | ABM | 1.0 ug DNA | 818.4 EUR |
DBNDD2 Polyclonal Antibody |
|||
| A56823 | EpiGentek |
|
|
DBNDD2 Antibody, HRP conjugated |
|||
| 1-CSB-PA863102HB01HU | Cusabio |
|
|
|
Description: A polyclonal antibody against DBNDD2. Recognizes DBNDD2 from Human. This antibody is HRP conjugated. Tested in the following application: ELISA |
|||
DBNDD2 Recombinant Protein (Rat) |
|||
| RP197372 | ABM | 100 ug | Ask for price |
DBNL Lentiviral Vector (Rat) (EF1a) (pLenti-GIII-EF1a) |
|||
| LV626190 | ABM | 1.0 ug DNA | 818.4 EUR |
DBNL Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV791419 | ABM | 1.0 ug DNA | 379.2 EUR |
DBNL Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV791421 | ABM | 1.0 ug DNA | 379.2 EUR |
DBNL Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV791425 | ABM | 1.0 ug DNA | 379.2 EUR |
DBN1 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-C-term-HA) |
|||
| LV660314 | ABM | 1.0 ug DNA | 1626 EUR |
DBNDD2 Antibody, FITC conjugated |
|||
| 1-CSB-PA863102HC01HU | Cusabio |
|
|
|
Description: A polyclonal antibody against DBNDD2. Recognizes DBNDD2 from Human. This antibody is FITC conjugated. Tested in the following application: ELISA |
|||
DBNDD2 Recombinant Protein (Human) |
|||
| RP008785 | ABM | 100 ug | Ask for price |
DBNDD2 Recombinant Protein (Mouse) |
|||
| RP127931 | ABM | 100 ug | Ask for price |
DBNDD2 Recombinant Protein (Mouse) |
|||
| RP127934 | ABM | 100 ug | Ask for price |
DBNDD2 Recombinant Protein (Mouse) |
|||
| RP127937 | ABM | 100 ug | Ask for price |
DBNDD2 Recombinant Protein (Mouse) |
|||
| RP127940 | ABM | 100 ug | Ask for price |
DBNDD2 3'UTR Luciferase Stable Cell Line |
|||
| TU005581 | ABM | 1.0 ml | 1825.2 EUR |
Dbndd2 3'UTR Luciferase Stable Cell Line |
|||
| TU203167 | ABM | 1.0 ml | Ask for price |
Dbndd2 3'UTR Luciferase Stable Cell Line |
|||
| TU104865 | ABM | 1.0 ml | Ask for price |
DBNL Lentiviral Vector (Human) (EF1a) (pLenti-GIII-EF1a) |
|||
| LV791420 | ABM | 1.0 ug DNA | 379.2 EUR |
DBNL Lentiviral Vector (Human) (EF1a) (pLenti-GIII-EF1a) |
|||
| LV791426 | ABM | 1.0 ug DNA | 379.2 EUR |
DBN1 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-GFP-2A-Puro) |
|||
| LV660315 | ABM | 1.0 ug DNA | 1695.6 EUR |
DBN1 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-RFP-2A-Puro) |
|||
| LV660316 | ABM | 1.0 ug DNA | 1695.6 EUR |
DBNDD2 Antibody, Biotin conjugated |
|||
| 1-CSB-PA863102HD01HU | Cusabio |
|
|
|
Description: A polyclonal antibody against DBNDD2. Recognizes DBNDD2 from Human. This antibody is Biotin conjugated. Tested in the following application: ELISA |
|||
DBNDD2 Polyclonal Antibody, HRP Conjugated |
|||
| A56824 | EpiGentek |
|
|
DBNDD2 Polyclonal Antibody, FITC Conjugated |
|||
| A56825 | EpiGentek |
|
|
DBNDD2 Polyclonal Antibody, Biotin Conjugated |
|||
| A56826 | EpiGentek |
|
|
DBNL Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-C-term-HA) |
|||
| LV626186 | ABM | 1.0 ug DNA | 818.4 EUR |
Human Dysbindin domain-containing protein 2 (DBNDD2) |
|||
| 1-CSB-EP863102HU | Cusabio |
|
|
|
Description: Recombinant Human Dysbindin domain-containing protein 2(DBNDD2) expressed in E.coli |
|||
DBNL Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-GFP-2A-Puro) |
|||
| LV626187 | ABM | 1.0 ug DNA | 888 EUR |
DBNL Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-RFP-2A-Puro) |
|||
| LV626188 | ABM | 1.0 ug DNA | 888 EUR |
DBNL Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV-C-term-HA) |
|||
| LV791422 | ABM | 1.0 ug DNA | 379.2 EUR |
DBNL Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV-GFP-2A-Puro) |
|||
| LV791417 | ABM | 1.0 ug DNA | 448.8 EUR |
DBNL Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV-RFP-2A-Puro) |
|||
| LV791418 | ABM | 1.0 ug DNA | 448.8 EUR |
DBNL Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV-GFP-2A-Puro) |
|||
| LV791423 | ABM | 1.0 ug DNA | 448.8 EUR |
DBNL Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV-RFP-2A-Puro) |
|||
| LV791424 | ABM | 1.0 ug DNA | 448.8 EUR |
Is has been clearly demonstrated that valproate is related to a excessive danger of CM/NDD, whereas lamotrigine and levetiracetam are comparatively secure. However, proof is much less express for different ASM. Reported dangers differ relying on the measurement and origin of the underlying examine inhabitants, the definition of publicity and outcomes, and different features of the examine design. Increased collaboration between information sources to extend pattern measurement are fascinating.
0